Last €3.64 EUR
Change Today -0.035 / -0.95%
Volume 269.3K
As of 12:15 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

evotec ag (EVT) Snapshot

Open
€3.70
Previous Close
€3.68
Day High
€3.70
Day Low
€3.60
52 Week High
11/5/13 - €5.18
52 Week Low
08/28/13 - €2.55
Market Cap
479.1M
Average Volume 10 Days
1.1M
EPS TTM
€-0.21
Shares Outstanding
131.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EVOTEC AG (EVT)

Related News

No related news articles were found.

evotec ag (EVT) Related Businessweek News

No Related Businessweek News Found

evotec ag (EVT) Details

Evotec AG, together with its subsidiaries, provides drug discovery solutions for pharmaceutical and biotechnology companies, and academic institutions worldwide. Its services comprise target ID and validation, hit identification, compound management, chemistry, ADME (absorption, distribution, metabolism and excretion) profiling, proteomics, reagent production, in vitro pharmacology, in vivo pharmacology, and integrated services. The company has various products under clinical stage comprising DiaPep277 for diabetes type 1; EVT3021 for Alzheimer's disease; EVT201 for insomnia; Somatoprim for Acromegaly; EVT1032 for TRD; EVT401 inflammation; and ND³ for oncology. It also has various pre-clinical stage products, including ND³ for pain and oncology; endometriosis products; and EVT770 for diabetes type 2/1, as well as discovery stage products comprising EVT070 for diabetes type 2; and various products for inflammation, diabetes type 2, diabetes type 2/1, kidney disease, and Alzheimer’s disease. The company has alliances and partnerships with various companies comprising AstraZeneca AB, Bayer Pharma AG, Boehringer Ingelheim Pharma GmbH & Co. KG, CHDI Foundation, Inc., MedImmune, LLC/AstraZeneca PLC, Genentech, Inc., the Jain Foundation, Janssen Pharmaceuticals, Inc., Johnson & Johnson Innovation, Ono Pharmaceutical Co., Ltd., UCB Pharma, and Fraunhofer Institute for Molecular Biology and Applied Ecology; and collaboration with Eternygen GmbH. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany.

Founded in 1993

evotec ag (EVT) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: €601.0K
Chief Financial Officer and Member of the Man...
Total Annual Compensation: €360.0K
Chief Operating Officer and Member of the Man...
Total Annual Compensation: €409.0K
Chief Scientific Officer and Member of the Ma...
Total Annual Compensation: €372.0K
Compensation as of Fiscal Year 2013.

evotec ag (EVT) Key Developments

Evotec AG Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Evotec AG reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. The company reported revenue of $91,121,000, income from operations of $25,429,000, income before income taxes of $19,735,000, net income attributable to common stockholders of $17,773,000 or $0.22 per diluted share against revenue of $89,175,000, loss from operations of $16,938,000, loss before income taxes of $69,947,000, net loss attributable to common stockholders of $64,935,000 or $0.82 per diluted share a year ago. EBITDA was $42,547,000 against LBITDA of $42,407,000 a year ago. Adjusted EBITDA was $45,523,000 against $43,431,000 a year ago. Adjusted net loss was $32,185,000 or $0.41 per diluted share against $28,874,000 or $0.35 per diluted share a year ago. The increase in adjusted EBITDA was due mostly to revenue growth and operating leverage in Merchant Acquiring and Payment Processing businesses. The increase in Adjusted Net Income was driven mainly by adjusted EBITDA growth, lower levels of operating depreciation and amortization expense, and lower cash taxes. Adjusted net income per diluted share increased 17% to $0.41 compared with $0.35 in the prior year. For the six months, the company reported revenue of $178,331,000, income from operations of $50,318,000, income before income taxes of $40,102,000, net income attributable to common stockholders of $35,979,000 or $0.45 per diluted share against revenue of $176,514,000, income from operations of $37,337,000, loss before income taxes of $64,424,000, net loss attributable to common stockholders of $59,463,000 or $0.78 per diluted share a year ago. EBITDA was $86,362,000 against LBITDA of $4,089,000 a year ago. Adjusted EBITDA was $90,747,000 against $85,182,000 a year ago. Adjusted net income was $64,171,000 or $0.81 per diluted share against $56,362,000 or $0.70 per diluted share a year ago. Net cash from operating activities was $67,537,000 against net cash used in operating activities of $13,902,000 a year ago. Purchase of property and equipment was $3,895,000 against $4,384,000 a year ago. Acquisition of intangible assets was $5,841,000 against $7,927,000 a year ago.

Evotec AG, Q2 2014 Earnings Call, Aug 12, 2014

Evotec AG, Q2 2014 Earnings Call, Aug 12, 2014

Evotec to Collaborate with Fraunhofer in Joint Drug Discovery Programmes

Evotec AG announced an exclusive strategic collaboration with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME in several disease areas through the combination of the relevant platforms of both organizations for internal and external drug discovery projects. This alliance expands Evotec's already powerful drug discovery platform with access to a broad range of complementary and highly innovative platforms and capabilities to progress own innovate projects and provides additional capabilities for customers and partners of Evotec and IME, respectively. The deal follows the joint decision of Evotec, Fraunhofer-Gesellschaft and the City of Hamburg to integrate the European ScreeningPort GmbH into the IME thereby forming the first Fraunhofer life science institution in the City of Hamburg.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EVT:GR €3.64 EUR -0.035

EVT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EVT.
View Industry Companies
 

Industry Analysis

EVT

Industry Average

Valuation EVT Industry Range
No financial data is available for EVT.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EVOTEC AG, please visit www.evotec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.